Document |
Document Title |
WO/2023/250017A1 |
Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate w...
|
WO/2023/247596A1 |
The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
WO/2023/247590A1 |
The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
WO/2023/246839A1 |
The present invention provides a salt of a compound with GLP-1R agonist activity, as represented by formula (I), and/or a crystal form, and preparation and pharmaceutical use, wherein a pharmaceutically acceptable salt is selected from a...
|
WO/2023/246925A1 |
Disclosed in the present invention are compounds or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers or isotope labeled compounds thereof. The compounds are as shown in formula (I)....
|
WO/2023/241137A1 |
The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, and an organic electroluminescent apparatus and an electronic device comprising same. The nitrog...
|
WO/2023/241136A1 |
The present application relates to the technical field of organic electroluminescent materials, and provides a heterocyclic compound, and an organic electroluminescent apparatus and an electronic device comprising same. The heterocyclic ...
|
WO/2023/240134A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
WO/2023/239768A1 |
The present application provides tricyclic triazolo compounds I that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
|
WO/2023/239729A1 |
The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable s...
|
WO/2023/232966A1 |
Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...
|
WO/2023/232776A1 |
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
WO/2023/233130A1 |
The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...
|
WO/2023/227946A1 |
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
|
WO/2023/225041A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
|
WO/2023/223346A1 |
The present invention relates to an improved process for the preparation of Edoxaban intermediate and further preparation of Edoxaban or its pharmaceutically acceptable salts.
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
WO/2023/217230A1 |
The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
|
WO/2023/218023A1 |
The present invention relates to compounds of the formula (I) Formula (I) wherein Ar1, R1, R2, R3, X1, X2, Y, and Z are as described in the description, to their preparation, to pharmaceutically 5 acceptable salts thereof, and to their u...
|
WO/2023/217906A1 |
The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
|
WO/2023/215494A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
WO/2023/164257A9 |
Provided herein are methods of inhibiting FSP1 and using FSP1 inhibitors as therapeutics for cancer.
|
WO/2023/215220A1 |
The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
|
WO/2023/215404A1 |
The present disclosure relates salts and the crystalline forms of certain 3',4,4',5-tetrahydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1
'-naphthalene] derivatives as well as pharmaceutical formulations and therapeutic uses thereof. The pr...
|
WO/2023/215449A1 |
This disclosure provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, that induce degradation of a BCL-XL protein. These are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosu...
|
WO/2023/207746A1 |
Provided are an asymmetric donor-receptor type near-infrared region II probe molecule, a method for preparing same, and use thereof. The probe molecule is represented by the following general formula (1). The emission spectrum of the pro...
|
WO/2023/207881A1 |
Provided herein are novel compounds, for example, compounds having a Formula A, B, C, D, E, or F, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...
|
WO/2023/212239A1 |
Described herein are compounds of formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
|
WO/2023/212549A1 |
Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
|
WO/2023/212237A1 |
Described herein are compounds of Formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
|
WO/2023/210569A1 |
The compound according to the present disclosure is a compound represented by general formula (1).
|
WO/2023/212231A1 |
Described herein are compounds of Formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
WO/2023/208124A1 |
The present application relates to a substituted piperidine carboxamide azaindane derivative, a method for preparing same, and use of a pharmaceutical composition containing the derivative or a deuterated derivative in medicine. Specific...
|
WO/2023/212548A1 |
Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
|
WO/2023/205701A1 |
The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
|
WO/2023/205366A1 |
Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and/or regenerati...
|
WO/2023/201780A1 |
Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
|
WO/2023/197744A1 |
The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, an organic electroluminescent device containing same, and an electronic apparatus. The nitrogen-...
|
WO/2023/196360A1 |
Disclosed herein are salt and solvate forms of. (1S,3'R,6'R,7'S,8'E,1 TS,12'R)-6-chloro-7'-methoxy-11 ',12'- dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'- [20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pent
acosa[8,16,18...
|
WO/2023/196361A1 |
Disclosed herein are crystalline and amorphous forms of (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-d
imethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-[20]oxa[
13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8...
|
WO/2023/194458A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use in a meth...
|
WO/2023/185704A1 |
The present invention relates to an isoxazole-heterocyclic derivative, a pharmaceutical composition and use, and specifically provides a compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautome...
|
WO/2023/184327A1 |
Provided herein are novel compounds, for example, compounds having a Formula I, Formula II-1 to II-7, Formula III-1 to III-9, IV, or V, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the comp...
|
WO/2023/192913A1 |
The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
|
WO/2023/183755A1 |
Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
|
WO/2023/177217A1 |
The present invention relates to: a novel aromatic heterocyclic compound to be used in an organic light-emitting diode; and the organic light-emitting diode comprising same.
|
WO/2023/174138A1 |
Disclosed are an amide compound as represented by formula I, and a preparation method therefor and the use thereof. The disclosed amide compound has selective inhibitory activity on Nav1.8 and can be used as a selective inhibitor for Nav...
|
WO/2023/178302A1 |
Natural product-like compounds are derived from the sesquiterpene lactone parthenolide. Methods are provided for the generation of novel natural product-like molecules obtained through the chemoenzymatic reelaboration and modification of...
|
WO/2023/168686A1 |
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
|